Medication for Addiction Treatment During COVID-19
As overdose rates rise, we need addiction treatment in hospitals now more than ever. This guidance outlines how to implement medication for addiction treatment (MAT) during predicted COVID-19 surges.
New HHS Practice Guidelines
Here’s the most important takeaway of the “HHS Practice Guidelines for the Administration of Buprenorphine for Treating Opioid Use Disorder”: All prescribers with a valid state license and DEA can register for an X wavier without mandatory training.
Blueprint for Hospital Opioid Use Disorder Treatment
This comprehensive resource is scalable for any health system, based on our model implemented at diverse sites that demonstrate feasibility at large and small, public and private, urban, and rural hospitals.
Substance Use Navigator Training 101
26 Aug 2021, 11:00 am
Improving and Sustaining your Program (Session 7)
CA Bridge leaders and team members will give us an update about the future and sustainability of the SUN role and your hospital’s MAT program. We will explore options to sustain and expand your program with specifics such as data collection, billing, and future funding opportunities.
CA Bridge is CADTP approved provider (CADTP Provider #216). Training sessions are one hour and approved for 1 continuing education credit. Contact SUN@cabridge.org for more information.